Plus Therapeutics, Inc. announced on April 23, 2025, the appointment of Kyle Guse, J.D., M.B.A., to its Board of Directors. Mr. Guse will serve as chair of the Audit Committee and on the Compensation Committee.
Mr. Guse brings 30 years of professional experience, including over a decade as Chief Financial Officer, General Counsel, and Secretary of a NASDAQ-listed company. He was also a Certified Public Accountant with a Big 4 accounting firm.
His extensive financial, transactional, and operational experience is expected to make an immediate positive impact on the board. This appointment aims to support the successful execution of Plus Therapeutics' business plan and drive stockholder value.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.